Roche Holdings Ltd ADR (RHHBY)

$48.40 -0.52 (-1.07%)
Market Cap 309.89B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 15.45
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 1,009,590
Avg Vol 1,987,024
Day's Range N/A - N/A
Shares Out 6.36B
Stochastic %K 86%
Beta 0.46
Analysts Sell
Price Target $47.73

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:55 AM
$FCN $LMDX $RHHBY $SPY Part 3 If proven, this may constitute: • fraudulent transfer (moving value out of reach of stakeholders) • breach of fiduciary duty (self-dealing, failing to maximize value) • market misrepresentation (omitting material assets and conflicts) • pre-pack phoenixing (continuing the enterprise through new entities) • insolvency abuse (undervalue transactions and director misfeasance)
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:54 AM
$FCN $LMDX $RHHBY $SPY Part 2 Shareholders received nothing because the insiders structured the process as an asset sale, not a company sale. Executives resigned at critical moments, reappeared in successor companies, and controlled the wind-down while holding shares, options, or conflicts of interest. Key pipeline assets (especially the TB test) were never independently valued, never disclosed properly, and never included in the sale consideration. This has the hallmarks of a coordinated scheme in which insiders: • declared insolvency while still holding valuable undeclared assets • transferred or shielded IP and operating capabilities • sold core assets to Roche at an undervalued price • preserved continuity in new entities they controlled • left shareholders with a hollow shell and zero recovery
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:53 AM
$LMDX $FCN $RHHBY $SPY $ELECTRADX $TAUN What my research tells me… Part 1 LumiraDx’s collapse was not a normal insolvency. The company’s valuable assets—its POC platform, TB test, SureSensors biosensor IP, Invita software/data, manufacturing know-how, and scientific talent—were quietly split, withheld, or redirected before and during the liquidation process. Roche acquired the commercial POC assets cheaply, while other high-value components resurfaced in spinouts and successor entities tied to former LMDX insiders (Invita/IVD Intelligence, ElectraDx, SureSensors continuity, LKM).
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 1:52 AM
$LMDX $FCN $LMDX $RHHBY $SPY $ELECTRADX $TAUN This continuity of personnel and capabilities, combined with the disappearance of Invita from LumiraDx’s asset disclosures and the lack of any corresponding impairment or divestiture explanation, suggests that material corporate value may have been shifted outside the reach of creditors and shareholders prior to insolvency. These indicators—timing of the separation, rapid balance-sheet deterioration, insider reaggregation at ElectraDx, absence of transparent asset-sale reporting, and failure to account for high-value digital IP—together support the reasonable inference that shareholders were deprived of assets that should have remained part of the LumiraDx estate. If verified, these would constitute serious breaches of fiduciary duty, potential fraudulent conveyance, and materially misleading financial reporting in my opinion.
0 · Reply
billymike
billymike Dec. 3 at 5:57 PM
$GANX $MRK or $RHHBY
0 · Reply
Quantumup
Quantumup Dec. 3 at 1:45 PM
TD Cowen Named $IONS a 2026 Best Idea, reiterated at a Buy, a $99 PT and said, Best Ideas 2026: New Launches And Key Pipeline Catalysts To Drive Upside $ARWR $TAK BCRX NVS $RHHBY - $PTCT TD Cowen added, We see robust sales growth in FY26 driven by Tryngolza in sHTG, Dawnzera in HAE, zilganersen in AxD, and incremental Spinraza growth. Key Ph3 data in '26 include Wainua in TTR-CM (H2) & pelacarsen in Lp(a) (H1). We see upside from overlooked catalysts: Ph3 bepi in HBV (H1), Ph2 BIIB080 in AD (mid-'26). RARE's GTX-102 Ph3 in Angelman (H2) should clarify ION582's future in this multi-$ B market.
0 · Reply
Quantumup
Quantumup Dec. 3 at 11:46 AM
William Blair🏁 $VRDN at an Outperform rating. $AMGN $NVS $ALPMY $RHHBY William Blair said, we are initiating coverage of Viridian with an Outperform rating and $47 fair value estimate, based on our belief that the company's anti-IGF-1R franchise represents a meaningful advance compared to Tepezza for the treatment of thyroid eye disease (TED). While we acknowledge that growth in the U.S. TED market has plateaued in recent years, we believe that new therapies offering a more convenient administration, cleaner picture of the adverse event profile of IGF-1R inhibition, and diplopia benefit in chronic disease have potential to grow the market. In particular, while we believe veligrotug has important advantages over Tepezza that could drive share capture and modest market expansion following a potential mid-2026 approval, we believe the bigger value driver is the subcutaneously administered VRDN-003, for which top-line Phase III data are expected in the first and second quarters of 2026.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 9:55 AM
$FCN $LMDX $RHHBY $SPY $ELECTRADX $TAUN This continuity of personnel and capabilities, combined with the disappearance of Invita from LumiraDx’s asset disclosures and the lack of any corresponding impairment or divestiture explanation, suggests that material corporate value may have been shifted outside the reach of creditors and shareholders prior to insolvency. These indicators—timing of the separation, rapid balance-sheet deterioration, insider reaggregation at ElectraDx, absence of transparent asset-sale reporting, and failure to account for high-value digital IP—together support the reasonable inference that shareholders were deprived of assets that should have remained part of the LumiraDx estate. If verified, these would constitute serious breaches of fiduciary duty, potential fraudulent conveyance, and materially misleading financial reporting in my opinion.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 9:52 AM
$LMDX $RHHBY $FCN $SPY $ELECTRADX $TAUN Here’s more info, imo from a shareholder perspective, the sequence of events surrounding Invita, LumiraDx, and ElectraDx raises multiple red flags consistent with potential asset diversion, insider preference, and misleading financial disclosure. Invita Technologies was formally separated from LumiraDx in September 2023—immediately prior to the company’s abrupt collapse in reported assets, including a documented loss of approximately $50 million in total and current assets within a two-month period. During the same window, LumiraDx executives publicly claimed that digital assets and software platforms remained part of the group, yet Invita—housing precisely those assets—was quietly removed from the balance sheet. Shortly thereafter, key technical, scientific, and digital-infrastructure personnel who had built LumiraDx’s proprietary systems resurfaced at ElectraDx, an entity controlled by Ron Zwanziger and other former LumiraDx insiders.
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 3:20 AM
$LMDX $RHHBY $SPY $FCN $ELECTRADX $TAUNS In my opinion, the timing of the Invita separation, the sudden deterioration of LumiraDx’s balance sheet, and the rapid emergence of ElectraDx with many of the same insiders is too aligned to ignore. Taken together, these events strongly suggest that key digital assets were repositioned ahead of insolvency, creating a continuity structure that benefited insiders while shareholders were wiped out.
0 · Reply
Latest News on RHHBY
No data available.
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:55 AM
$FCN $LMDX $RHHBY $SPY Part 3 If proven, this may constitute: • fraudulent transfer (moving value out of reach of stakeholders) • breach of fiduciary duty (self-dealing, failing to maximize value) • market misrepresentation (omitting material assets and conflicts) • pre-pack phoenixing (continuing the enterprise through new entities) • insolvency abuse (undervalue transactions and director misfeasance)
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:54 AM
$FCN $LMDX $RHHBY $SPY Part 2 Shareholders received nothing because the insiders structured the process as an asset sale, not a company sale. Executives resigned at critical moments, reappeared in successor companies, and controlled the wind-down while holding shares, options, or conflicts of interest. Key pipeline assets (especially the TB test) were never independently valued, never disclosed properly, and never included in the sale consideration. This has the hallmarks of a coordinated scheme in which insiders: • declared insolvency while still holding valuable undeclared assets • transferred or shielded IP and operating capabilities • sold core assets to Roche at an undervalued price • preserved continuity in new entities they controlled • left shareholders with a hollow shell and zero recovery
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 3:53 AM
$LMDX $FCN $RHHBY $SPY $ELECTRADX $TAUN What my research tells me… Part 1 LumiraDx’s collapse was not a normal insolvency. The company’s valuable assets—its POC platform, TB test, SureSensors biosensor IP, Invita software/data, manufacturing know-how, and scientific talent—were quietly split, withheld, or redirected before and during the liquidation process. Roche acquired the commercial POC assets cheaply, while other high-value components resurfaced in spinouts and successor entities tied to former LMDX insiders (Invita/IVD Intelligence, ElectraDx, SureSensors continuity, LKM).
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 4 at 1:52 AM
$LMDX $FCN $LMDX $RHHBY $SPY $ELECTRADX $TAUN This continuity of personnel and capabilities, combined with the disappearance of Invita from LumiraDx’s asset disclosures and the lack of any corresponding impairment or divestiture explanation, suggests that material corporate value may have been shifted outside the reach of creditors and shareholders prior to insolvency. These indicators—timing of the separation, rapid balance-sheet deterioration, insider reaggregation at ElectraDx, absence of transparent asset-sale reporting, and failure to account for high-value digital IP—together support the reasonable inference that shareholders were deprived of assets that should have remained part of the LumiraDx estate. If verified, these would constitute serious breaches of fiduciary duty, potential fraudulent conveyance, and materially misleading financial reporting in my opinion.
0 · Reply
billymike
billymike Dec. 3 at 5:57 PM
$GANX $MRK or $RHHBY
0 · Reply
Quantumup
Quantumup Dec. 3 at 1:45 PM
TD Cowen Named $IONS a 2026 Best Idea, reiterated at a Buy, a $99 PT and said, Best Ideas 2026: New Launches And Key Pipeline Catalysts To Drive Upside $ARWR $TAK BCRX NVS $RHHBY - $PTCT TD Cowen added, We see robust sales growth in FY26 driven by Tryngolza in sHTG, Dawnzera in HAE, zilganersen in AxD, and incremental Spinraza growth. Key Ph3 data in '26 include Wainua in TTR-CM (H2) & pelacarsen in Lp(a) (H1). We see upside from overlooked catalysts: Ph3 bepi in HBV (H1), Ph2 BIIB080 in AD (mid-'26). RARE's GTX-102 Ph3 in Angelman (H2) should clarify ION582's future in this multi-$ B market.
0 · Reply
Quantumup
Quantumup Dec. 3 at 11:46 AM
William Blair🏁 $VRDN at an Outperform rating. $AMGN $NVS $ALPMY $RHHBY William Blair said, we are initiating coverage of Viridian with an Outperform rating and $47 fair value estimate, based on our belief that the company's anti-IGF-1R franchise represents a meaningful advance compared to Tepezza for the treatment of thyroid eye disease (TED). While we acknowledge that growth in the U.S. TED market has plateaued in recent years, we believe that new therapies offering a more convenient administration, cleaner picture of the adverse event profile of IGF-1R inhibition, and diplopia benefit in chronic disease have potential to grow the market. In particular, while we believe veligrotug has important advantages over Tepezza that could drive share capture and modest market expansion following a potential mid-2026 approval, we believe the bigger value driver is the subcutaneously administered VRDN-003, for which top-line Phase III data are expected in the first and second quarters of 2026.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 9:55 AM
$FCN $LMDX $RHHBY $SPY $ELECTRADX $TAUN This continuity of personnel and capabilities, combined with the disappearance of Invita from LumiraDx’s asset disclosures and the lack of any corresponding impairment or divestiture explanation, suggests that material corporate value may have been shifted outside the reach of creditors and shareholders prior to insolvency. These indicators—timing of the separation, rapid balance-sheet deterioration, insider reaggregation at ElectraDx, absence of transparent asset-sale reporting, and failure to account for high-value digital IP—together support the reasonable inference that shareholders were deprived of assets that should have remained part of the LumiraDx estate. If verified, these would constitute serious breaches of fiduciary duty, potential fraudulent conveyance, and materially misleading financial reporting in my opinion.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 9:52 AM
$LMDX $RHHBY $FCN $SPY $ELECTRADX $TAUN Here’s more info, imo from a shareholder perspective, the sequence of events surrounding Invita, LumiraDx, and ElectraDx raises multiple red flags consistent with potential asset diversion, insider preference, and misleading financial disclosure. Invita Technologies was formally separated from LumiraDx in September 2023—immediately prior to the company’s abrupt collapse in reported assets, including a documented loss of approximately $50 million in total and current assets within a two-month period. During the same window, LumiraDx executives publicly claimed that digital assets and software platforms remained part of the group, yet Invita—housing precisely those assets—was quietly removed from the balance sheet. Shortly thereafter, key technical, scientific, and digital-infrastructure personnel who had built LumiraDx’s proprietary systems resurfaced at ElectraDx, an entity controlled by Ron Zwanziger and other former LumiraDx insiders.
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Dec. 3 at 3:20 AM
$LMDX $RHHBY $SPY $FCN $ELECTRADX $TAUNS In my opinion, the timing of the Invita separation, the sudden deterioration of LumiraDx’s balance sheet, and the rapid emergence of ElectraDx with many of the same insiders is too aligned to ignore. Taken together, these events strongly suggest that key digital assets were repositioned ahead of insolvency, creating a continuity structure that benefited insiders while shareholders were wiped out.
0 · Reply
Quantumup
Quantumup Dec. 2 at 11:54 AM
Jefferies⬆️the PT on $CELC to $134 from $106 and reiterated at a Buy rating. $NVS $RHHBY $AZN $LLY PFE Jefferies said in its note: We like the setup for CELC heading into 2026, w/ ph.Ill data in PIK3CAmut, expected late 1Q/2Q26, where we see a high likelihood of success, supported by our updated stats analysis informed by the PIK3CAwt study. Also, we anticipate a robust 2026 launch driven by major unmet need and believe pot'l upside in 1L remains underappreciated, adding further value. We see an attractive risk/reward profile and would-be buyers. PT to $134 (+$28).
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Nov. 29 at 3:08 PM
$LMDX $SPY $RHHBY $FCN Documented Events and Financial Outcomes in the LumiraDx Collapse 1. LumiraDx was once valued at $5 billion. 2. The Roche deal delivered only about $300 million. 3. Shareholders lost roughly $4.7 billion in value. 4. Ron Zwanziger and his affiliated family entities collectively owned approximately 25.5 percent of all LumiraDx common shares. 5. ElectraDx raised $14 million shortly after key LumiraDx resignations. Key R&D personnel and with POC tech. 6. Lumira Colombia was disposed of for near-zero value. 7. LumiraDx received multiple patents in mid and late 2024, after the company was already in dissolution. 8. The LumiraDx TB diagnostic patent was approved after the Roche transaction, meaning the technology was still active and valuable but never included in the sale valuation. 9. Invita Technologies was separated out prior to the Roche deal, removing assets from the group before the sale. 10. Shareholders ultimately recovered $0.
1 · Reply
TaleOfTheTape
TaleOfTheTape Nov. 28 at 4:23 PM
$RHHBY Could Immunovia AB be an aquisition target for $RHHBY They just received final Medicare payment rate (897$) for their PancreaSure test, for stage I and II pancreatic canser, one of the deadliest cancers globally. Their test has high sensitivity and specificity. Extremely low market cap of 17 mill. $. They are already in the process of securing Medicare/ Medicade reimbursement. This could be an interesting takeover candidate.
0 · Reply
DmcMouse
DmcMouse Nov. 28 at 2:46 PM
$LMDX So this means were getting Roche shares? $RHHBY
1 · Reply
ar_mando
ar_mando Nov. 27 at 5:26 PM
$LMDX $RHHBY finally one sensible post in a good while. That’s exactly what happened in short. All Ron believers can ask themselves who was the man behind all this, who moved assets to Electra & Invita, who negotiated and sold for peanuts POC to Roche? Who benefited from it? Who now has fresh debt free company with all the ex Lumira IP’s technologies and assets? You must be blind not to see that. Question for crystal ball owners: in your opinion who is the magic person who is going to pay us? Roche? For what? They never told they’re going to buy a whole company. They bought an asset and the deal is closed.
0 · Reply
DmcMouse
DmcMouse Nov. 27 at 5:07 PM
$LMDX $RHHBY My opinion on what happened with LumiraDx: Retail didn’t just get “unlucky” — the valuable pieces were carved out long before the liquidation wrapped up. Here’s what the outcome looks like: • POC platform → moved to Roche • Care Solutions → moved to Invita • IP + key engineers → moved to ElectraDx • Creditors → protected and settled • Retail shareholders → left with zero That’s the structure we all see now. The tech survived. The teams survived. The partners survived. The original LMDX shell didn’t. And yes — the shares still showing in our accounts a year later tells me the cleanup was never completed cleanly or correctly. Something in the backend was never finalized. Not accusing anyone of wrongdoing — just laying out the observable facts and sharing my own view. Hopefully the little guys get something in the end. Everyone else already got taken care of. NFA
2 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Nov. 27 at 1:35 PM
$LMDX $RHHBY $FCN $ELECTRADX Hey there ☝️, it's time to talk turkey.
0 · Reply
TheRationalTrade
TheRationalTrade Nov. 27 at 3:26 AM
$RHHBY Added to watch list.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Nov. 27 at 3:18 AM
$LMDX $RHHBY 👁️👁️
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Nov. 27 at 3:17 AM
$LMDX $RHHBY $ELECTRADX 👁️👁️
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Nov. 27 at 3:15 AM
$FCN $LMDX $RHHBY $SPY 👁️👁️
0 · Reply
Austero
Austero Nov. 25 at 6:18 PM
$CUBT 2026 🎯 $BHC $JNJ $RHHBY $TAK
1 · Reply